我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
1
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
HSA
Health Sciences Authority
<p><strong>1 INDICATIONS AND USAGE</strong></p> <p><strong>1.1 Prophylaxis of Invasive <em>Aspergillus</em> and <em>Candida</em> Infections</strong><br>  Posaconazole delayed-release tablets are indicated for prophylaxis of invasive <em>Aspergillus</em> and <em>Candida</em> infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.<br>  Posaconazole delayed-release tablets 100 mg are indicated in patients 13 years of age and older.</p>
暂无资讯文章